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It was reported that in laboratory animals total (Gunduz et al,
1979) or partial (Braunschweiger et al, 1982) tumour removal may
stimulate cell proliferation in macro-metastatic foci, due to an in
serum detectable growth-stimulating factor (Fisher et al, 1989).
More recently, the direct study of micro-metastases, proved that
for some experimental tumours producing angiogenesis inhibitor
factors, primary tumour removal caused a switch of micrometa-
static foci to the angiogenic phenotype, resulting in growth of
metastases (Holmgren et al, 1995). All these findings suggest that,
at least in animal models, surgery should be considered as a major
perturbing factor for metastasis development. No similar findings
about surgery-induced tumour growth changes, if any, have been
achieved in humans. Therefore, in spite of the very wide use of
surgery to treat neoplasms, its effect on residual tumour growth
dynamics is virtually unknown. 
We report here an investigation on breast cancer mortality
versus time in patients undergoing mastectomy alone as primary
treatment and in patients not receiving any form of therapy. The
comparison between the two mortality patterns suggests a possible
influence of surgery on the course of the disease. 
MATERIALS AND METHODS 
A total of 1173 patients who from 1964 through to 1980 entered
into three different clinical trials at the Milan Cancer Institute,
with mastectomy alone as primary treatment for operable breast
cancer, were retrospectively evaluated. Primary tumour was
treated by radical or modified radical mastectomy and no patient
received postoperative radiotherapy or chemotherapy. After
surgery, patients were examined every 6–8 months during the first
3 years and once a year thereafter. Treatment failure was defined
as the first clinically documented evidence of new disease mani-
festation(s). A detailed description of patients and treatments is
reported in Demicheli et al (1996). 
As a historical database of untreated patients, the series reported
by Bloom et al (1962) was considered. A total of 250 patients with
breast cancer, admitted to the Middlesex Hospital for terminal
care, were studied. No patient was treated with any form of
surgery, radiation therapy or hormone therapy. For a detailed
description of patients the interested reader can consult the orig-
inal paper. 
From the published mortality data of the Bloom series and from
our own data we calculated the yearly hazard rate of death. Our
application involved a discretization of the time axis, and the
timing of the death risk was studied by estimating the event-
specific hazard rate as the conditional probability of dying in a
time interval, given that the patient was alive at the beginning of
the interval. The yearly discrete hazard of death was calculated by
means of the life-table method (Statistical Sciences, 1995). 
RESULTS 
The death-specific hazard rate for all patients is displayed in
Figure 1. The curve obtained from the Bloom series shows a single
surge, peaking at about the 4th–5th year, followed by a near
constant plateau. On the contrary, the curve resulting from Milan
data shows a double-peaked pattern, with a first major mortality
surge reaching the maximum at the 3rd–4th year and a second well
evident mortality increase near the 8th year. Moreover, the hazard
rates of the Bloom series are quite higher than the corresponding
values of the Milan series. 
DISCUSSION 
For the Milan series, the time distribution of first treatment failure
had been already reported to be double-peaked (Demicheli et al,
1996). The cause-specific hazard function for local-regional recur-
rences and distant metastases presented an early peak approxi-
mately at 18 months after surgery, a second peak at approximately
60 months with a plateau-like tail extending out to 15 years. This
finding was confirmed by a similar analysis on a second series of
877 node positive patients receiving adjuvant CMF (Demicheli 
et al, 1999). Even a preliminary analysis of Milan mortality
showed two peaks, with impressive quantitative and qualitative
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similarity to another recently published series of surgically treated
patients (Karrison et al, 1999; Demicheli et al, 2000). Therefore,
the double-peaked pattern of breast cancer natural history (recur-
rence and mortality) after primary tumour removal should be
considered as confirmed. A reasonable hypothesis to explain the
observed patterns of the hazard functions is to assume that, as in
animal models, primary tumour removal may result in sudden
acceleration of metastatic process by stimulating tumour cell
proliferation and/or angiogenesis (Demicheli et al, 1997).
According to this view, multiple peaks should only appear for
patients undergoing surgical treatment. 
It is obvious that to compare surgery treated patients with
untreated patients only retrospective studies could be performed.
Therefore, the first step was to document the natural history of the
untreated disease, in order to establish a baseline by which to
judge the effects of surgery. Breast cancer has been considered a
treatable disease for at least the last several hundred years. So,
series of untreated but well-documented patients are uncommon.
Among them most authors consider the Bloom series a reliable
database with a fair degree of accuracy. 
The most important result emerging from this study is the occur-
rence of two peaks in the hazard rate curve for the Milan series
(patients who underwent mastectomy), and only one peak for the
Middlesex series (untreated patients) (Figure 1). 
Many caveats, a few of which are listed below, need to be
considered when comparing the two curves. The Bloom series
resulted from a retrospective investigation covering several
decades. Death for breast cancer (verified by necropsy) was
required as selection criteria for the studied patients, who were
generally admitted to the hospital with advanced disease (74.4%
stage IV, 23.2% stage III) for terminal care. As the duration of the
disease was based on statements made by the patient or her rela-
tives about the onset of the initial symptom (a lump in the breast in
83% of cases), the survival time is affected by a certain degree of
uncertainty. Moreover, as all patients eventually died (although
that required 16 years, remarkably), the hazard rate was elevated.
Due to fluctuations in hazards towards the end of the observed
time, we limited the analysis to 12 years. 
Milan patients were prospectively recruited. Selection criteria
consisted of histological confirmation of resectable unilateral
breast cancer with no evidence of distant metastases. Following
the disease recurrence some form of treatment was given
(hormone therapy, chemotherapy, radiation therapy). Survival was
defined from the date of mastectomy, disregarding the sympto-
matic time prior to surgery, and mortality included deaths for any
cause. As at the time of analysis approximately 50% of patients
were alive, Milan data show a lower hazard rate compared to the
Bloom series. 
Despite these concerns, we believe that, as more direct compar-
isons between treated and untreated patients are not available, the
comparison between the curves obtained from Bloom and Milan
data should be considered. The comparison gives some support 
to the hypothesis that in breast cancer surgical removal of the
primary tumour may induce changes in the growth kinetics of
metastatic foci, like in animal models. In our opinion a reasonable
hypothesis, explaining the different pattern of death hazard func-
tions, may be a multi-fold consequence of mastectomy, i.e. the
‘cure’ of a significant fraction of patients, and the change of the
‘natural’ recurrence and death timing for some of the others. If that
is so, it will be relevant both to the screening policy and to the
treatment strategy for breast cancer. 
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Figure 1 Mortality of breast cancer patients: comparison between
untreated patients (Bloom series) and patients undergoing mastectomy
(Milan series). (A) Hazard function for death for 250 never treated women
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